Jennifer Villa

Dr. Jennifer Villa

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2012 in Emerging Infectious Diseases
Verified
Journal Article
Open access
EVEsther Viedma
Esther Viedma
Carlos JuanCarlos Juan
Carlos Juan
JVJennifer Villa
Jennifer Villa
LBLaura Barrado
Laura Barrado
MOM. Ángeles Orellana
M. Ángeles Orellana
FCFernando Chaves
Fernando Chaves
A total of 183 patients were colonized or infected with multidrug-resistant Pseudomonas aeruginosa isolates at a hospital in Spain during 2007–2010; prevalence increased over this period from 2.8% to 15.3%. To characterize these isolates, we performed molecular epidemiologic and drug resistance analysis. Genotyping showed that 104 (56.8%) isolates belonged to a single major clone (clone B), which was identified by multilocus sequence typing as sequence type (ST) 175. This clone was initially isolated from 5 patients in 2008, and then isolated from 23 patients in 2009 and 76 patients in 2010. PCR analysis of clone B isolates identified the blaVIM-2 gene in all but 1 isolate, which harbored blaIMP-22. ST175 isolates were susceptible to only amikacin (75%) and colistin (100%). Emergence of the ST175 clone represents a major health problem because it compromises therapy for treatment of P. aeruginosa nosocomial infections.

18 May 2016 in Transplant Infectious Disease
Verified
Journal Article
Closed access
PDF file
JOJ. Origüen
J. Origüen
MFM. Fernández‐Ruiz
M. Fernández‐Ruiz
FLFrancisco Lopez-Medrano
Francisco Lopez-Medrano
TRT. Ruiz‐Merlo
T. Ruiz‐Merlo
EGE. González
E. González
JAJ.M. Aguado
J.M. Aguado

1 July 2015 in International Journal of Antimicrobial Agents
Verified
Journal Article
Closed access
PBPatricia Brañas
Patricia Brañas
JVJennifer Villa
Jennifer Villa
EVEsther Viedma
Esther Viedma
JMJesús Mingorance
Jesús Mingorance
MOM. Angeles Orellana
M. Angeles Orellana
FCFernando Chaves
Fernando Chaves

1 August 2010 in Journal of Clinical Microbiology
Verified
Journal Article
Closed access
PDF file
CGCarmen Gómez-González
Carmen Gómez-González
JAJoshi Acosta
Joshi Acosta
JVJennifer Villa
Jennifer Villa
LBLaura Barrado
Laura Barrado
FSFrancisca Sanz
Francisca Sanz
FCFernando Chaves
Fernando Chaves
Most Staphylococcus aureus small-colony variants (SCVs) are auxotrophs for menadione, hemin, or thymidine but rarely for CO 2 . We conducted a prospective investigation of all clinical cases of CO 2 -dependent S. aureus during a 3-year period. We found 14 CO 2 -dependent isolates of S. aureus from 14 patients that fulfilled all requirements to be considered SCVs, 9 of which were methicillin resistant. The clinical presentations included four cases of catheter-related bacteremia, one complicated by endocarditis; two deep infections (mediastinitis and spondylodiscitis); four wound infections; two respiratory infections; and two cases of nasal colonization. Pulsed-field gel electrophoresis typing showed that the 14 isolates were distributed into 4 types corresponding to sequence types ST125- agr group II ( agr II), ST30- agr III, ST34- agr III, and ST45- agr I. An array hybridization technique performed on the 14 CO 2 -dependent isolates and 20 S. aureus isolates with normal phenotype and representing the same sequence types showed that all possessed the enterotoxin gene cluster egc , as well as the genes for α-hemolysin and δ-hemolysin; biofilm genes icaA , icaC , and icaD ; several microbial surface components recognizing adhesive matrix molecules (MSCRAMM) genes ( clfA , clfB , ebh , eno , fib , ebpS , sdrC , and vw ); and the isaB gene. Our study confirms the importance of CO 2 -dependent SCVs of S. aureus as significant pathogens. Clinical microbiologists should be aware of this kind of auxotrophy because recovery and identification are challenging and not routine. Further studies are necessary to determine the incidence of CO 2 auxotrophs of S. aureus , the factors that select these strains in the host, and the genetic basis of this type of auxotrophy.

9 August 2019 in Antimicrobial Resistance & Infection Control
Verified
Journal Article
Open access
PDF file
LMLAURA MOLES
LAURA MOLES
MGMarta Gomez
Marta Gomez
EMElena Moroder
Elena Moroder
EJEsther Jimenez
Esther Jimenez
DEDiana Escuder
Diana Escuder
JRJuan Miguel Rodríguez
Juan Miguel Rodríguez
Nosocomial sepsis is the main problem that preterms have to face during their stay at neonatal intensive care units (NICU). Serratia marcescens is an emerging cause of preterm sepsis but its epidemiology is still largely unknown. Consequently, the aims of this study were to know the rate of preterms colonized by S. marcescens during their stay at the NICU and the characteristics and evolution of the S. marcescens population, including the susceptibility to clinically relevant antibiotics. Twenty-six preterm infants born with a gestational age ≤ 32 weeks and/or weigh ≤1500 g were included in the study. Samples of meconium and feces (n = 92) were collected during their first month of life of the infants, together with feeding samples after their pass through enteral feeding tubes (n = 37). Samples were inoculated on MacConkey agar plates. The isolates identified as S. marcescens were genotyped using RAPD and PFGE; and antibiotics susceptibility was performed in a Vitek 2 system. A total of 179 S. marcescens isolates were obtained from the samples. PFGE profiling and cluster analysis allowed the classification of the isolates into 7 different S. marcescens clones. PFGE patterns 1 and 3 were the dominant strains in the fecal samples colonizing 31 and 35% of the infants, respectively. Those isolates causing bacteremia in two infants clustered in PFGE pattern 3. S. marcescens is a bacterial species closely associated to the NICU environment. It can be frequently isolated from preterm’s feces although only some genetic lineages seem to be associated to sepsis. Enteral feeding tubes act as important reservoirs to keep the S. marcescens population in the NICU. The local ethic committee approved this trial with the reference 09/157.

1 May 2014 in International Journal of Antimicrobial Agents
Verified
Journal Article
Closed access
JVJennifer Villa
Jennifer Villa
EVEsther Viedma
Esther Viedma
PBPatricia Brañas
Patricia Brañas
MOMª Angeles Orellana
Mª Angeles Orellana
JOJoaquín R. Otero
Joaquín R. Otero
FCFernando Chaves
Fernando Chaves